drugset / Trial / NCT06989437
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.
Timeline
- Start
- 2025-10-03
- Primary completion
- 2028-01-17
- Completion
- 2029-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ponsegromab | Monoclonal antibody | 200 mg | Subcutaneous |
| Subject | ponsegromab | Monoclonal antibody | 400 mg | Subcutaneous |